pI: 4.5591 |
Length (AA): 141 |
MW (Da): 16319 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 2 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
3 | 141 | 2c21 (A) | 3 | 141 | 99.99 | 0 | 1 | 2.24 | -1.64 |
3 | 141 | 2c21 (A) | 3 | 141 | 99.99 | 0 | 1 | 2.20682 | -1.27 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Resolution | Method | # Atoms | # Residues | Dep. Date | Pub. Date | Mod. Date |
---|---|---|---|---|---|---|
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 60-80% percentile | amastigotes. | Fernandes MC |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_127627)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT1G08110 | lactoylglutathione lyase |
Brugia malayi | Bm1_18670 | lactoylglutathione lyase |
Candida albicans | CaO19.6058 | glyoxalase I |
Candida albicans | CaO19.13479 | glyoxalase I |
Dictyostelium discoideum | DDB_G0291265 | glyoxylase I |
Drosophila melanogaster | Dmel_CG1707 | CG1707 gene product from transcript CG1707-RA |
Escherichia coli | b1651 | glyoxalase I, Ni-dependent |
Homo sapiens | ENSG00000124767 | glyoxalase I |
Leishmania braziliensis | LbrM.34.2920 | glyoxalase I |
Leishmania donovani | LdBPK_353060.1 | glyoxalase I |
Leishmania infantum | LinJ.35.3060 | glyoxalase I,trypanothione-dependent glyoxalase I |
Leishmania major | LmjF.35.3010 | glyoxalase I,trypanothione-dependent glyoxalase I |
Leishmania mexicana | LmxM.34.3010 | glyoxalase I,trypanothione-dependent glyoxalase I |
Loa Loa (eye worm) | LOAG_03565 | hypothetical protein |
Mus musculus | ENSMUSG00000024026 | glyoxalase 1 |
Neospora caninum | NCLIV_064370 | Lactoylglutathione lyase (EC 4.4.1.5), related |
Oryza sativa | 4338324 | Os05g0295800 |
Onchocerca volvulus | OVOC11536 | Lactoylglutathione lyase homolog |
Plasmodium berghei | PBANKA_0933900 | glyoxalase I, putative |
Plasmodium falciparum | PF3D7_1113700 | glyoxalase I |
Plasmodium knowlesi | PKNH_0911300 | glyoxalase I, putative |
Plasmodium vivax | PVX_091330 | glyoxalase I, putative |
Plasmodium yoelii | PY00733 | lactoylglutathione lyase, putative |
Saccharomyces cerevisiae | YML004C | lactoylglutathione lyase GLO1 |
Trypanosoma cruzi | TcCLB.510743.70 | lactoylglutathione lyase-like protein, putative |
Trypanosoma cruzi | TcCLB.510659.240 | lactoylglutathione lyase-like protein, putative |
Toxoplasma gondii | TGME49_248400 | glyoxalase I, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
b1651 | Escherichia coli | non-essential | goodall |
PBANKA_0933900 | Plasmodium berghei | Dispensable | plasmo |
TGME49_248400 | Toxoplasma gondii | Probably non-essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania donovani | 103413 415029 | |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 85261-23-0; Drug: 104951-62-4; Drug: 204446-06-0; Drug: 277310-54-0; Drug: 277310-55-1; Drug: 277310-56-2; Drug: 277310-57-3; Drug: 277310-58-4; Drug: 277310-59-5; Drug: 277310-60-8; Drug: 277310-61-9; Drug: 33812-60-1; Drug: 104928-26-9; Drug: 104928-27-0; Drug: 104928-28-1; Drug: 104928-29-2; Drug: 104951-63-5; Drug: 204445-92-1; Drug: 204445-99-8; Drug: 277310-53-9 . some chemical inhibitors reduced glyoxalase activity. | References: | 10821719 | |
growth (GO:0040007) | normal (PATO:0000461) | single cell organism (CARO:0000064) | inferred from in-silico analysis (ECO:0000043) | Leishmania infantum | No drug identifiers listed for this gene. | |
Annotator: | crowther@u.washington.edu. | Comment: | computer modeling suggests that GLO1 and GLO2 are not good targets because their activities don't greatly affect methylglyoxal concentration. | References: | 15885089 | |
catalytic activity (GO:0003824) | decreased (PATO:0000468) | in vitro (MI:0492) | inferred from specific protein inhibition (ECO:0000020) | Leishmania major | 103413 307979 415029 555923 | |
Annotator: | crowther@u.washington.edu. | Comment: | Drug: 886970-70-3; Drug: 886970-71-4 . chemical inhibitors selectively reduce Leishmania but not human GLO1 activity (or vice versa). | References: | 16430697 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.6
Compound | Source | Reference |
---|---|---|
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References | |
Curated by TDRTargets | References |
Species | Known druggable target | Linked compounds | Reference |
---|---|---|---|
Homo sapiens | glyoxalase I | Compounds | References |
Plasmodium falciparum | glyoxalase I | Compounds | References |
Saccharomyces cerevisiae | lactoylglutathione lyase GLO1 | Compounds | References |
Trypanosoma cruzi | lactoylglutathione lyase-like protein, putative | Compounds | References |
Target | Type | Source | Notes |
---|---|---|---|
LmjF.35.3010 | purified protein | BRENDA | A protein with this EC number or name or sequence has been purified from Leishmania major ( 2 ) |